NGEN — Nervgen Pharma Balance Sheet
0.000.00%
Last trade - 00:00- $343.10m
- $327.28m
Annual balance sheet for Nervgen Pharma, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 16.9 | 22.5 | 11.7 | 17.3 | 22.1 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.064 | 0.027 | 0.25 | 0.513 | 0.089 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 17.4 | 23.1 | 12.5 | 19 | 22.8 |
| Net Property, Plant And Equipment | 0.003 | 0.295 | 0.2 | 0 | — |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 17.9 | 23.9 | 13.2 | 19.5 | 23.2 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.08 | 10.2 | 15.1 | 16.9 | 19.7 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.08 | 10.4 | 15.2 | 16.9 | 19.7 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 16.8 | 13.5 | -2.01 | 2.58 | 3.48 |
| Total Liabilities & Shareholders' Equity | 17.9 | 23.9 | 13.2 | 19.5 | 23.2 |
| Total Common Shares Outstanding |